4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line

In Vivo

Volumn 21, Issue 2, 2007, Pages 381-387

  Inoue, Yuzuru ^a   Nakayama, Yoshifumi ^a   Sako, Tatsuhiko ^a   Minagawa, Noritaka ^a   Abe, Yukio ^a   Nagato, Masaru ^a   Kadowaki, Koji ^a   Katsuki, Takefumi ^a   Matsumoto, Kentaro ^a   Tsurudome, Yosuke ^a   Shibao, Kazunori ^a   Hirata, Keiji ^a   Nagata, Naoki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Apoptosis; Caspase; Colorectal cancer; Fas; Retinoid; TAC 101

Indexed keywords

4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDO]BENZOIC ACID; BENZOIC ACID DERIVATIVE; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR; DEATH RECEPTOR 3; FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; TAC 101; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CALORIMETRY; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 34047202156     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Lee MO, Han SY, Jiang S, Park JH and Kim SJ: Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem Pharmacol 59: 485-496, 2000.
2. Herold C, Ganslmayer M, Ocker M, Blauberger S, Zopf S, Hahn EG and Schuppan D: Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. Int J Oncol 23: 751-756, 2003.
3. Ocker M, Herold C, Ganslmayer M, Hahn EG and Schuppan D: The synthetic retinoid adapalene inhibits proliferation and induces apoptosis in colorectal cancer cells in vitro. Int J Cancer 107: 453-459, 2003.
4. Um SJ, Han HS, Kwon YJ, Park SH, Rho YS, Sin HS and Park JS: Novel retinoic acid derivative ABPN has potent inhibitory activity on cell growth and apoptosis in cancer cells. Int J Cancer 107: 1038-1046, 2003.
5. Lippman SM, Kessler JF and Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treat Rep 71: 391-405, 1987.
6. Lotan R: Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res 54: 1987s-1990s, 1994.
7. Webber MM and Waghray A: Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res 1: 755-761, 1995.
8. Lingen MW, Polverini PJ and Bouck NP: Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 74: 476-483, 1996.
9. Benbow U, Schoenermark MP, Orndorff KA, Givan AL and Brinckerhoff CE: Human breast cancer cells activate procollagenase-1 and invade type I collagen: invasion is inhibited by all-trans retinoic acid. Clin Exp Metastasis 17: 231-238, 1999.
10. Schoenermark MP, Mitchell TI, Rutter JL, Reczek PR and Brinckerhoff CE: Retinoid-mediated suppression of tumor invasion and matrix metalloproteinase synthesis. Ann NY Acad Sci 878: 466-486, 1999.
11. Zhu Q, Liu JY, Yang CM, Xu HW, Zhang AZ, Cui Y, Wang HB, Qin CY and Li YQ: Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol 18: 1071-1077, 2006.
12. Gianni M, Ponzanelli I, Mologni L, Reichert U, Rambaldi A, Terao M and Garattini E: Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ 7: 447-460, 2000.
13. Nagy L, Thomazy VA, Heyman RA and Davies PJ: Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ 5: 11-19, 1998.
14. Stennicke HR and Salvesen GS: Caspases - controlling intracellular signals by protease zymogenactivation. Biochim Biophys Acta 1477: 299-306, 2000.
15. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
16. Antonsson B: Bax and other pro-apoptotic Bcl-2 family "killer-proteins" and their victim the mitochondrion. Cell Tissue Res 306: 347-361, 2001.
17. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RA, Shudo K, Hong WK and Lotan R: Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 57: 4931-4939, 1997.
18. Murakami K, Wierzba K, Sano M, Shibata J, Yonekura K, Hashimoto A, Sato K and Yamada Y: TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. Clin Exp Metastasis 16: 323-331, 1998.
19. Sakukawa R, Murakami K, Ikeda T, Yamada Y and Saiki I: Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells. Oncol Res 10: 287-293, 1998.
20. Murakami K, Matsuura T, Sano M, Hashimoto A, Yonekura K, Sakukawa R, Yamada Y and Saiki I: 4-[3,5-Bis(trimethylsilyl) benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals. Clin Exp Metastasis 16: 633-643, 1998.
21. Fujimoto K, Hosotani R, Doi R, Wada M, Lee JU, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S and Imamura M: Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int J Cancer 81: 637-644, 1999.
22. Murakami K, Sakukawa R, Sano M, Hashimoto A, Shibata J, Yamada Y and Saiki I: Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101. Clin Cancer Res 5: 2304-2310, 1999.
23. Murakami K, Yamaura T, Suda K, Ohie S, Shibata J, Toko T, Yamada Y and Saiki I: TAC-101 (4-[3,5-bis(trimethylsilyl) benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma. Jpn J Cancer Res 90: 1254-1261, 1999.
24. Shibata J, Murakami K, Aoyagi Y, Oie S, Hashimoto A, Suzuki K, Sano M, Wierzba TT and Yamada Y: The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer. Anticancer Res 20: 3583-3590, 2000.
25. Shibata J, Murakami K, Wierzba K, Aoyagi Y, Hashimoto A, Sano M, Toko T and Yamada Y: Anticancer effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its antiinvasive activity. Anticancer Res 20: 3169-3176, 2000.
26. Oikawa T, Murakami K, Sano M, Shibata J, Wierzba K and Yamada Y: A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases. Jpn J Cancer Res 92: 1225-1234, 2001.
27. Suzuki N, Aoki D, Oie S, Horiuchi M, Hasegawa Y, Ezawa S, Suzuki A, Susumu N, Hosoi F, Kitazato K and Nozawa S: A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma. Gynecol Oncol 94: 643-649, 2004.
28. Sako T, Nakayama Y, Minagawa N, Inoue Y, Onitsuka K, Katsuki T, Tsurudome Y, Shibao K, Hirata K, Nagata N, Ohie S, Kohno K and Itoh H: 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression. In Vivo 19: 125-132, 2005.
29. Minagawa N, Nakayama Y, Inoue Y, Onitsuka K, Katsuki T, Tsurudome Y, Shibao K, Hirata K, Sako T, Nagata N, Ohie S, Kohno K and Itoh H: 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. Oncol Res 14: 407-414, 2004.
30. Michel S, Jomard A and Demarchez M: Pharmacology of adapalene. Br J Dermatol 139(Suppl 52): 3-7, 1998.
31. Ulukaya E and Wood EJ: Fenretinide and its relation to cancer. Cancer Treat Rev 25: 229-235, 1999.
32. Zhao X and Spanjaard RA: The apoptotic action of the retinoid CD437/ AHPN: diverse effects, common basis. J Biomed Sci 10: 44-49, 2003.
33. Lippman SM and Lotan R: Advances in the development of retinoids as chemopreventive agents. J Nutr 130: 479S-482S, 2000.
34. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P and Moras D: Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J 19: 2592-2601, 2000.
35. Liu J, Guo L, Jun-Wei L, Liu N and Li H: All-trans retinoic acid modulates fas expression and enhances chemosensitivity of human medulloblastoma cells. Int J Mol Med 5: 145-149, 2000.
36. Danforth DN and Zhu Y: Conversion of Fas-resistant to Fas-sensitive MCF-7 breast cancer cells by the synergistic interaction of interferon-gamma and all-trans retinoic acid. Breast Cancer Res Treat 94: 81-91, 2005.
37. Sun SY, Yue P, Hong WK and Lotan R: Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 60: 6537-6543, 2000.
38. DiPietrantonio AM, Hsieh TC, Juan G, Traganos F, Darzynkiewicz Z and Wu JM: Fenretinide-induced caspase-3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res 60: 4331-4335, 2000.
39. You KR, Shin MN, Park RK, Lee SO and Kim DG: Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells. Hepatology 34: 1119-1127, 2001.
40. Jin F, Liu X, Zhou Z, Yue P, Lotan R, Khuri FR, Chung LW and Sun SY: Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res 65: 6354-6363, 2005.
41. Friesen C, Herr I, Krammer PH and Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574-577, 1996.
42. Fulda S, Sieverts H, Friesen C, Herr I and Debatin KM: The CD95 (APO-1/ Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57: 3823-3829, 1997.
43. Fulda S, Los M, Friesen C and Debatin KM: Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 76: 105-114, 1998.